Amy Laurendeau

Partner

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Amy Laurendeau has extensive experience defending class and mass tort actions. She routinely defends pharmaceutical and medical device companies in coordinated proceedings and other high-stakes trials and appeals. She has defended class actions involving prescription and over-the-counter medicines, cosmetics, electronics, pet food, and insurance, to name a few.

In addition to her mass tort and class action work, Amy has represented clients across varied industries in complex business litigation matters, ranging from contract disputes, to trade secret violations, to insurance coverage and bad faith claims.

VIEW MORE

Honors & Awards

  • Recognized by The Legal 500 in the “Product liability, mass tort and class action - consumer products” category (2017)
  • National Institute for Trial Advocacy (NITA) Faculty Member (2017)
  • Named a “Rising Star” in General Litigation in a survey conducted by Law & Politics Media Inc. and published in Los Angeles Magazine and the Southern California edition of Super Lawyers (2009, 2010, 2011)

Admissions

Bar Admissions

  • California

Court Admissions

  • U.S. Supreme Court
  • U.S. Court of Appeals for Ninth Circuit
  • U.S. District Court for the Central, Eastern, Northern and Southern Districts of California
  • U.S. District Court for the District of Colorado

Education

  • University of Michigan, J.D., 1998: cum laude
  • University of Toledo, B.A., English, 1995

Professional Activities

Amy is an established leader in the Orange County legal community. She is the Immediate Past President of the Federal Bar Association, Orange County Chapter, having served as President for the 2017 - 2018 term.

She served for several years as a Board Member for the Constitutional Rights Foundation, Orange County and on the Orange County Bar Association’s Judiciary Committee, responsible for evaluating judicial candidates.

Amy was an Inaugural Emerging Leader for Emory Law's Institute for Complex Litigation and Mass Claims.

Amy also holds several leadership positions within O’Melveny, including serving as the Firmwide Talent Development Partner.

Speaking Engagements and Publications

  • Panelist, Mass Torts Made Perfect (April 2019)
  • “The Federal Courts:  The Latest on Lexicon,” Emory Law Institute for Complex Litigation and Mass Claims, State-Federal Coordination Conference (March 2019; conference Co-Chair)
  • “Settlement Strategies,” Emory Law Institute for Complex Litigation and Mass Claims, FJC/JPML Conference (December 2016)
  • Moderator: “Complex Case Management,” Los Angeles County Bar Association Complex Courts Symposium (November 2016)
  • “The Importance of Ascertainability in Consumer Products Class Actions,” Association of Business Trial Lawyers Report (Fall 2016)
  • “Article III Standing and Class Certification After Spokeo,” Strafford CLE (July 2016)
  • “Pharmaceuticals: Federally Approved Labels and Preemption,” George Mason University Law School Judicial Symposium on Civil Justice Issues (May 2016)
  • “Developments in Ethics,” O’Melveny & Myers CLE Marathon (December 2015; January 2013)
  • “Preemption in Class Actions,” Bridgeport Consumer Class Actions Conference (January 2015)
  • “Writing Skills, Tips & Tricks for Insurance Lawyers,” ExecSense (April 2010)
  • “Bad Faith in Insurance Claims: Strategies for Prosecuting and Defending Against Claims of Insurer Misconduct,” Strafford CLE (July 2009; October 2008)
  • Moderator: “Protective Orders, Discovery Motions, Settlement Conferences and the Magistrate Judge Pilot Program,” Federal Bar Association, Orange County Chapter (November 2007)
  • Representing major pharmaceutical manufacturer in nationwide litigation brought by states, municipalities and other entities involving opioid medicines.
  • Representing major pet food maker in more than 20 putative class actions, brought on behalf of more than 300 named plaintiffs, in 11 different federal courts.
  • Trial counsel for major pharmaceutical company in JCCP involving more than 10,000 personal injury claims. Obtained complete defense jury verdict in first (and only, to date) California bellwether trial.
  • Defending Amylin Pharmaceuticals, a subsidiary of AstraZeneca, against claims brought by hundreds of plaintiffs in personal injury cases involving Byetta®, an injectable medication for type-2 diabetes, in a federal Multi-District Litigation (MDL), California Judicial Council Coordinated Proceeding (JCCP) and other courts around the country.
  • Obtained summary judgment in several JCCP Byetta® bellwether cases—including the first case scheduled for trial—on the grounds that plaintiffs could not prove that a different warning would have changed their doctors’ prescribing decisions.
  • Obtained judgment for Amylin in federal court complaint based on plaintiff’s failure to satisfy pleading requirements.  Argued appeal in the Sixth Circuit, which affirmed dismissal.
  • Represented medical device manufacturer in appeal from adverse judgment. Obtained US$50 million reduction in punitive damages award on appeal.
VIEW MORE